Plavix® (clopidogrel) is a type of blood thinner designed to prevent blood clots.
Approved by the FDA in August 2006, Plavix® is manufactured by Sanofi-Aventis and Bristol-Myers Squibb and is used in patients to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions. It is most often prescribed to patients diagnosed with coronary artery disease, peripheral vascular disease, or cerebrovascular disease. According to its clinicalpharmocology, Plavix® (clopidogrel) is indicated for prevention of vascular ischemic events in patients with symptomatic atherosclerosis, treatment of acute coronary syndrome and treatment of ST elevation MI (STEMI). In conjunction with an aspirin regimen, Plavix® (clopidogrel) is also commonly used for blood clot prevention after placement of intracoronary stents. It can also be used as an alternative anti-platelet/anti-coagulant drug for aspirin intolerant patients.
Unfortunately, Plavix® (clopidogrel) has been found to cause a number of serious and potentially life-threatening complications.